Literature DB >> 24352877

Female reproductive factors, menopausal hormone use, and Parkinson's disease.

Rui Liu1, Donna Baird, Yikyung Park, Neal D Freedman, Xuemei Huang, Albert Hollenbeck, Aaron Blair, Honglei Chen.   

Abstract

The objective of this study was to examine the associations of reproductive factors and exogenous hormone use with risk of Parkinson's disease (PD) among postmenopausal women. The study comprised 119,166 postmenopausal women aged 50 to 71 years in the NIH-AARP Diet and Health Study, who completed a baseline questionnaire in 1995-1996 and a follow-up survey in 2004-2006. A total of 410 self-reported PD diagnoses were identified between 1995 and 2006. Multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression models. PD risk was not significantly associated with female reproductive factors including age at menarche, age at first live birth, parity, and age at menopause. For example, compared with women with natural menopause at age 50 to 54 years, the ORs were 1.18, (95% CI, 0.78-1.79) for women with natural menopause aged <45, 1.19 (95% CI, 0.88-1.61) for those aged 45 to 49, and 1.33 (95% CI, 0.91-1.93) for those aged 55 or older. We found that oral contraceptive use for ≥10 years (vs. never used) was associated with lower PD risk (OR, 0.59; 95% CI, 0.38-0.92), but shorter use showed no association. Use of menopausal hormone therapy showed inconsistent results. Compared with non-hormone users at baseline, current hormone users for <5 years showed a higher risk of PD (OR, 1.52; 95% CI, 1.11-2.08). However, no associations were observed for past hormone users or current users of ≥5 years. Overall, this large prospective study provides little support for an association between female reproductive factors and PD risk. Our findings on long-term oral contraceptive use and current hormone therapy warrant further investigations.
© 2013 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; cohort studies; menopausal hormone therapy; reproductive factors

Mesh:

Year:  2013        PMID: 24352877      PMCID: PMC4057969          DOI: 10.1002/mds.25771

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  35 in total

Review 1.  Mechanisms of progesterone-induced neuroprotection.

Authors:  Meharvan Singh
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

2.  Trends in the content and use of oral contraceptives in the United States, 1964-88.

Authors:  B B Gerstman; T P Gross; D L Kennedy; R C Bennett; D K Tomita; B V Stadel
Journal:  Am J Public Health       Date:  1991-01       Impact factor: 9.308

3.  Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease.

Authors:  R A Popat; S K Van Den Eeden; C M Tanner; V McGuire; A L Bernstein; D A Bloch; A Leimpeter; L M Nelson
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

4.  Effects of female sex steroids on Parkinson's disease in postmenopausal women.

Authors:  E Strijks; J A Kremer; M W Horstink
Journal:  Clin Neuropharmacol       Date:  1999 Mar-Apr       Impact factor: 1.592

5.  Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study.

Authors:  P J Blanchet; J Fang; K Hyland; L A Arnold; M M Mouradian; T N Chase
Journal:  Neurology       Date:  1999-07-13       Impact factor: 9.910

6.  Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen.

Authors:  Alberto Ascherio; Marc G Weisskopf; Eilis J O'Reilly; Marjorie L McCullough; Eugenia E Calle; Carmen Rodriguez; Michael J Thun
Journal:  Am J Epidemiol       Date:  2004-11-15       Impact factor: 4.897

7.  Gender differences in Parkinson's disease.

Authors:  Charlotte A Haaxma; Bastiaan R Bloem; George F Borm; Wim J G Oyen; Klaus L Leenders; Silvia Eshuis; Jan Booij; Dean E Dluzen; Martin W I M Horstink
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-10       Impact factor: 10.154

8.  Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause.

Authors:  W A Rocca; J H Bower; D M Maraganore; J E Ahlskog; B R Grossardt; M de Andrade; L J Melton
Journal:  Neurology       Date:  2007-08-29       Impact factor: 9.910

9.  Intermittent infusion of progesterone potentiates whereas continuous infusion reduces amphetamine-stimulated dopamine release from ovariectomized estrogen-primed rat striatal fragments superfused in vitro.

Authors:  D E Dluzen; V D Ramirez
Journal:  Brain Res       Date:  1987-03-17       Impact factor: 3.252

Review 10.  Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.

Authors:  Bin Liu; Dean E Dluzen
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-07       Impact factor: 2.557

View more
  14 in total

Review 1.  The Role of Estrogen in Brain and Cognitive Aging.

Authors:  Jason K Russell; Carrie K Jones; Paul A Newhouse
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

2.  The complexities of hormonal influences and risk of Parkinson's disease.

Authors:  Connie Marras; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2014-04-30       Impact factor: 10.338

3.  Associations between cancer and Parkinson's disease in U.S. elderly adults.

Authors:  D Michal Freedman; Jincao Wu; Honglei Chen; Eric A Engels; Lindsey R Enewold; Neal D Freedman; James J Goedert; Ralph W Kuncl; Mitchell H Gail; Ruth M Pfeiffer
Journal:  Int J Epidemiol       Date:  2016-03-17       Impact factor: 7.196

Review 4.  The relevance of gender in Parkinson's disease: a review.

Authors:  Marina Picillo; Alessandra Nicoletti; Vincenza Fetoni; Barbara Garavaglia; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

5.  Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach.

Authors:  Cynthia D J Kusters; Kimberly C Paul; Aline Duarte Folle; Adrienne M Keener; Jeff M Bronstein; Lars Bertram; Johnni Hansen; Steve Horvath; Janet S Sinsheimer; Christina M Lill; Beate R Ritz
Journal:  Mov Disord       Date:  2021-08-23       Impact factor: 9.698

Review 6.  Age Cutoff for Early-Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease.

Authors:  Raja Mehanna; Katarzyna Smilowska; Jori Fleisher; Bart Post; Taku Hatano; Maria Elisa Pimentel Piemonte; Kishore Raj Kumar; Victor McConvey; Baorong Zhang; Eng-King Tan; Rodolfo Savica
Journal:  Mov Disord Clin Pract       Date:  2022-09-10

7.  Hormone replacement therapy and Parkinson's disease risk in women: a meta-analysis of 14 observational studies.

Authors:  Peifu Wang; Jilai Li; Shi Qiu; Honfeng Wen; Jichen Du
Journal:  Neuropsychiatr Dis Treat       Date:  2014-12-31       Impact factor: 2.570

8.  Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease.

Authors:  Bjørg Johanne Warø; Jan O Aasly
Journal:  Brain Behav       Date:  2017-12-07       Impact factor: 2.708

9.  Gender Differences in Age-Related Striatal Dopamine Depletion in Parkinson's Disease.

Authors:  Jae Jung Lee; Jee Hyun Ham; Phil Hyu Lee; Young H Sohn
Journal:  J Mov Disord       Date:  2015-09-10

10.  Association Analysis of Proteasome Subunits and Transporter Associated with Antigen Processing on Chinese Patients with Parkinson's Disease.

Authors:  Ming-Shu Mo; Wei Huang; Cong-Cong Sun; Li-Min Zhang; Luan Cen; You-Sheng Xiao; Guo-Fei Li; Xin-Ling Yang; Shao-Gang Qu; Ping-Yi Xu
Journal:  Chin Med J (Engl)       Date:  2016-05-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.